Capital is reaching enterprise platforms, speech infrastructure and vertical applications. The ledger below prioritises announcements within 24 October 2025–23 October 2026. Dates are announcement dates unless otherwise stated; financing terms are not independently audited by this desk.
New financing rounds
| Announcement date | Company and segment | Disclosed financing | Valuation disclosed in the cited evidence | Lead investors | Buyer relevance—desk interpretation |
|---|---|---|---|---|---|
| 14 October 2026 | Confido Health; healthcare operations | $12.5m Series A extension | Not disclosed | Z47 | Expands the comparison beyond voice reception into administrative execution. Fierce Healthcare reports that the extension closed in February; October is the disclosure date, not necessarily the funding date. (fiercehealthcare.com) |
| 24 June 2026 | Assort Health; patient-access agents | $120m Series C | $1.2bn | Menlo Ventures | Relevant to outpatient groups and health systems evaluating a broader patient-access platform. (fiercehealthcare.com) |
| 12 May 2026 | Vapi; voice-agent infrastructure and orchestration | $50m Series B | Not disclosed in the cited company release | Peak XV | Relevant to engineering-led builds and integrators; assess operating support separately from API capability. (globenewswire.com) |
| 4 February 2026 | ElevenLabs; speech and conversational agents | $500m Series D | $11bn at this round | Sequoia Capital | Supports a supplier spanning both underlying speech technology and application-layer agents. This valuation was subsequently superseded by the tender transaction below. (elevenlabs.io) |
| 15 January 2026 | Parloa; enterprise customer-experience agents | $350m Series D | $3bn | General Catalyst | Relevant to enterprise procurement; financing does not establish deployment quality on a buyer’s workload. (parloa.com) |
| 13 January 2026 | Deepgram; speech and voice infrastructure | $130m Series C | $1.3bn | AVP | Relevant even when purchased indirectly through an application vendor; identify dependencies in the proposed stack. (deepgram.com) |
| 15 December 2025 | PolyAI; enterprise conversational automation | $86m Series D | Not disclosed | Georgian, Hedosophia and Khosla Ventures | Relevant to buyers seeking enterprise deployment and operating support rather than a developer toolkit alone. (poly.ai) |
Desk calculation: the six individually identified rounds from PolyAI through Assort total $1.236bn: $86m + $130m + $350m + $500m + $50m + $120m. This is a selected-supplier subtotal—not total sector investment, US-only funding or annual customer expenditure. The Confido extension is shown separately because the reporting and closing dates differ. (poly.ai)
Which large headlines should not be added to that subtotal?
| Disclosure date | Activity | Correct classification | Why the distinction matters |
|---|---|---|---|
| 30 September 2026 | ElevenLabs announced a completed $300m employee tender offer at a $22bn valuation, led by Wellington and T. Rowe Price | Employee/shareholder liquidity transaction, not another $300m primary operating-capital round | A newer valuation does not mean the full transaction value became company cash. (elevenlabs.io) |
| 27 April 2026 | Avoca announced more than $125m across Seed, Series A and Series B, at a $1bn valuation; Series B led by Meritech and General Catalyst | Multi-round cumulative disclosure | The release does not establish a $125m standalone Series B. Adding the headline to separately reported earlier rounds risks double counting. (prnewswire.com) |
Avoca also said it had surpassed eight figures of ARR during 2025 and was on track to book $1bn in jobs during 2026. The latter was a forward-looking customer job-value claim as of 27 April 2026, not realised annual revenue for Avoca. (prnewswire.com)